Follitropin Alpha
- Atc Codes:G03GA05
- CAS Codes:56832-30-5#110909-60-9#146479-72-3
- PHARMGKB ID:56832-30-5#110909-60-9#146479-72-3
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Gonal-F; Belgium: Gonal-F; Bulgaria: Gonal-F; Cyprus: Gonal-F; Czech Republic: Gonal-F; Denmark: Gonal-F; Estonia: Gonal-F; Finland: Gonal-F; France: Gonal-F; Germany: Gonal-F; Greece: Gonal-F; Hungary: Gonal-F; Ireland: Gonal-F; Italy: Gonal-F; Latvia: Gonal-F; Lithuania: Gonal-F; Malta: Gonal-F; Poland: Gonal-F; Portugal: Gonal-F; Romania: Gonal-F; Slovakia: Gonal-F; Slovenia: Gonal-F; Spain: Gonal F; Sweden: Gonal-F; UK: Gonal-F.
North America
Canada: Gonal-F; USA: Gonal-F.
Latin America
Argentina: Gonal-F; Brazil: Gonal-F; Mexico: Gonal-F.
Asia
Japan: Gonal-F.
Drug combinations
Follitropin Alpha and Lutropin Alpha
Chemistry
Follitropin Alpha: α-subunit: C~437~H~682~N~122~O~134~S~13~. Mw: 10205.69. Follicle-stimulating hormone, glycoform α. Chorionic gonadotropin (human α-subunit protein moiety reduced). CAS-56832-30-5.
β-subunit: C~538~H~833~N~145~O~171~S~13~. Mw: 12485.10. Follicle-stimulating hormone (human clone λ 15B β-subunit protein moiety reduced). CAS-110909-60-9. CAS-146479-72-3.
Pharmacologic Category
Hormones and Synthetic Substitutes; Gonadotropins. Ovulation Stimulator. (ATC-Code: G03GA05).
Mechanism of action
Follitropin α is a human FSH preparation of recombinant DNA origin. Follitropins stimulate ovarian follicular growth in women who do not have primary ovarian failure, and stimulate spermatogenesis in men with hypogonadotrophic hypogonadism.
Therapeutic use
Ovulation induction in patients where cause of infertility is functional and not caused by primary ovarian failure. Development of multiple follicles with Assisted Reproductive Technology. Spermatogenesis induction.
Pregnancy and lactiation implications
Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multiple births reported. Use not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to follitropins or any component of the formulation. High levels of FSH indicating primary gonadal failure (ovarian or testicular). Uncontrolled thyroid or adrenal dysfunction. Tumor of ovary, breast, uterus, hypothalamus, testis, or pituitary gland. Abnormal vaginal bleeding of undetermined origin. Ovarian cysts or enlargement not due to polycystic ovary syndrome. Pregnancy.
Warnings and precautions
Ovarian enlargement, and ovarian hyperstimulation syndrome have occurred. Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) and thromboembolic events reported. Multiple births may result from use of these medications.